Effect of HDL-Raising Drugs on Cardiovascular Outcomes: A Systematic Review and Meta-Regression

Exercise-mediated changes in high-density lipoprotein: Impact on form and function

(2013) Alisa Blazek et al.   AMERICAN HEART JOURNAL

High-Density Lipoprotein Subfractions - What the Clinicians Need to Know

(2013) Angela Pirillo et al.   CARDIOLOGY

Cholesteryl Ester Transfer Protein Inhibitors in the Treatment of Dyslipidemia: A Systematic Review and Meta-Analysis

(2013) Chuanwei Li et al.   PLoS One

Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial

(2012) Thomas F. Lüscher et al.   EUROPEAN HEART JOURNAL

How to control residual cardiovascular risk despite statin treatment: Focusing on HDL–cholesterol

(2012) Soo Lim et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome

(2012) Gregory G. Schwartz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy

(2011)   NEW ENGLAND JOURNAL OF MEDICINE

Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease

(2010) Christopher P. Cannon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2009) David Moher et al.   PLOS MEDICINE

Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone

(2008) M J Forrest et al.   BRITISH JOURNAL OF PHARMACOLOGY